Sniprbiome is a leading CRISPR microbiome company dedicated to developing CRISPR-based medicines for the effective and safe treatment of challenging diseases. With a mission to provide hope for the future, Sniprbiome aims to revolutionize the management of untreatable and difficult-to-treat conditions by employing precision killing of bacteria and leveraging the human microbiota. Their innovative approach and cutting-edge technology have attracted significant attention, evidenced by their impressive $50M Series A funding, one of the largest in Europe.

The company boasts a team of over 40 highly skilled scientists, primarily holding PhD degrees, who have made noteworthy discoveries and secured multiple patent families, with 28 patents already granted in the US. Sniprbiome's ultimate goal is to engineer microbiomes using CRISPR technology to combat serious and life-threatening diseases, including IBD, multi-drug resistant infections, and cancer. Join their dynamic and collaborative team in Copenhagen, Denmark, if you are passionate about inventing tomorrow's medicine